29 March 2024 – The European Medicines Agency (EMA) is reminding applicants and holders of marketing authorizations that revised fees will be implemented for all applications, excluding pharmacovigilance procedures, starting from 1 April 2024.

Annually, the European Commission approves a regulation modifying the fees payable to the Agency, taking into account the inflation rate in the European Union from the preceding year.

For more information, see here.